Genentech, a member of the Roche Group, will return to NewLink Genetics rights to cancer candidate GDC-0919 (navoximod), NewLink acknowledged today. GDC-0919 is an indoleamine-pyrrole 2,3-dioxygenase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results